Skip to main content
. 2019 Jul 3;7(8):1093–1101. doi: 10.1177/2050640619862721

Figure 3.

Figure 3.

Number of patients with unacceptable to neutral bloating (Likert scale 1–4) at evaluation time points. Day 28: end of first-line treatment; Day 56: end of crossover treatment; Day 86: after 30 days' follow-up; Day 116: after 60 days' follow-up. Broken lines indicate follow-up period. PPT: pea protein and tannins from grape seed extract; XG: xyloglucan; XOS: xylo-oligosaccharides.